Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%...
Saved in:
| Published in | BMC psychiatry Vol. 10; no. 1; p. 45 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
10.06.2010
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur.
Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media.
Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue.
Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS.
ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. |
|---|---|
| AbstractList | Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (& 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489 Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections ([less than] 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. Abstract Background Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Methods Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Results Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Conclusions Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. Trial Registration ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489 Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur.BACKGROUNDOlanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur.Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media.METHODSHealthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media.Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue.RESULTSInjection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue.Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS.CONCLUSIONSManufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS.ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489.TRIAL REGISTRATIONClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. BACKGROUND: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. METHODS: Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. RESULTS: Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. CONCLUSIONS: Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. TRIAL REGISTRATION: ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489 Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. Background Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections ([less than] 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Methods Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Results Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Conclusions Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. Trial Registration ClinicalTrials.gov ID; URL: |
| ArticleNumber | 45 |
| Audience | Academic |
| Author | Stickelmeyer, Mary Mitchell, Malcolm I Johnson, Jason Bergstrom, Richard F Sorsaburu, Sebastian Kothare, Prajakti Sanchez-Felix, Manuel V Detke, Holland C McDonnell, David P |
| AuthorAffiliation | 2 F. Bergstrom PK/PD Consulting LLC, Carmel, Indiana, USA 1 Lilly Research Laboratories, Indianapolis, Indiana, USA |
| AuthorAffiliation_xml | – name: 2 F. Bergstrom PK/PD Consulting LLC, Carmel, Indiana, USA – name: 1 Lilly Research Laboratories, Indianapolis, Indiana, USA |
| Author_xml | – sequence: 1 givenname: David P surname: McDonnell fullname: McDonnell, David P – sequence: 2 givenname: Holland C surname: Detke fullname: Detke, Holland C – sequence: 3 givenname: Richard F surname: Bergstrom fullname: Bergstrom, Richard F – sequence: 4 givenname: Prajakti surname: Kothare fullname: Kothare, Prajakti – sequence: 5 givenname: Jason surname: Johnson fullname: Johnson, Jason – sequence: 6 givenname: Mary surname: Stickelmeyer fullname: Stickelmeyer, Mary – sequence: 7 givenname: Manuel V surname: Sanchez-Felix fullname: Sanchez-Felix, Manuel V – sequence: 8 givenname: Sebastian surname: Sorsaburu fullname: Sorsaburu, Sebastian – sequence: 9 givenname: Malcolm I surname: Mitchell fullname: Mitchell, Malcolm I |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20537130$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFU0tv1DAQjlARfcCZG4rEgQvp-pU44YBUKh4rVYIDSNysiR9ZV4m92Nmi9o_wd3E27aqLWpEcknzzzTfjbybH2YHzTmfZS4xOMa6rBWYcF4SxnwVGBSufZEc75ODe-2F2HOMlQpjXJX6WHRJUUo4pOsr-fPNxLKy71HK03uVK9zbYzbCIWsEWiddOBT_o3Lp8nSDtxpj_tuMqj3Jlb_x6FbSzkI9Bw6jVHPI9uBtYW6fz3ruugKTuunxX522-XL5Ln1c6jrbbFoq5N_mg5QqcjcPz7KmBPuoXt8-T7Menj9_PvxQXXz8vz88uirbC1ViYmoJWhBJQFXBgTGqjgLQEg0FSNZw0gHmLDeUVZcYYVZGG0qrluuQ0XSfZctZVHi7FOtgBwrXwYMUW8KETEEYrey2owaxmjTHQMoYMaktcIZqKoAZqZcqk9X7WWm_aQSuZnArQ74nuR5xdic5fCVI3ZdmgJPBhFmitf0RgPyL9IKYhi2nIAiPBpi7e3HYR_K9N8lcMNkrdp4lov4mCM1Y1NarJ_5nJKMLptrHXM7ODZIR1xqfycmKLM0IRqTlCVWKdPsBKt9KDlWlxjU34XsKr-4btDnq3nolQzgQZfIxBGyHtuN2WpGz76cTTb_CAB4t_8u6kH8v4C_faDTc |
| CitedBy_id | crossref_primary_10_36290_psy_2022_029 crossref_primary_10_1186_s12888_014_0298_4 crossref_primary_10_2147_PGPM_S391401 crossref_primary_10_1097_JCP_0000000000000509 crossref_primary_10_1016_j_jemermed_2013_08_118 crossref_primary_10_1007_s40263_014_0216_9 crossref_primary_10_1097_JCP_0000000000001847 crossref_primary_10_1517_14656566_2011_553193 crossref_primary_10_1039_c3ra41967c crossref_primary_10_5498_wjp_v14_i4_582 crossref_primary_10_1080_17425247_2022_2106213 crossref_primary_10_1111_bcpt_12394 crossref_primary_10_1016_S0034_7450_14_60074_3 crossref_primary_10_1097_FTD_0000000000001317 crossref_primary_10_1080_14737175_2017_1371014 crossref_primary_10_1097_JCP_0000000000001091 crossref_primary_10_1177_20451253221113093 crossref_primary_10_4045_tidsskr_13_0335 crossref_primary_10_1177_2045125312446395 crossref_primary_10_1186_s12888_015_0669_5 crossref_primary_10_1186_1471_244X_12_51 crossref_primary_10_1007_s40263_020_00779_5 crossref_primary_10_1016_j_clinthera_2013_09_023 crossref_primary_10_1192_bjpo_bp_116_004382 crossref_primary_10_1002_hup_1225 crossref_primary_10_1007_s40263_013_0083_9 crossref_primary_10_1007_s11095_023_03470_8 crossref_primary_10_1016_j_ejps_2022_106253 crossref_primary_10_1007_s13760_021_01707_0 crossref_primary_10_1017_S1092852913000783 crossref_primary_10_1097_WNF_0000000000000329 crossref_primary_10_1002_phar_1313 crossref_primary_10_1186_1471_244X_10_43 crossref_primary_10_1021_acs_molpharmaceut_4c00550 crossref_primary_10_9740_mhc_2022_08_263 crossref_primary_10_3109_15622975_2012_739708 crossref_primary_10_1097_WNF_0b013e3182854f70 crossref_primary_10_1586_14737175_2013_811984 crossref_primary_10_1097_JCP_0000000000001742 crossref_primary_10_2165_11587240_000000000_00000 crossref_primary_10_3109_15563650_2014_906213 crossref_primary_10_1186_s12888_015_0450_9 crossref_primary_10_1097_JCP_0000000000001073 crossref_primary_10_4137_JCNSD_S4091 crossref_primary_10_1517_14656566_2012_686169 crossref_primary_10_1080_14656566_2023_2228686 crossref_primary_10_1097_FTD_0000000000000041 crossref_primary_10_1517_14740338_2016_1141893 crossref_primary_10_1515_hmbci_2017_0004 crossref_primary_10_1136_emermed_2024_213972 crossref_primary_10_1177_1060028019831634 crossref_primary_10_1186_1471_244X_14_7 crossref_primary_10_2217_npy_11_24 crossref_primary_10_23736_S2532_1285_23_00195_7 crossref_primary_10_4137_CMPsy_S6659 crossref_primary_10_1017_S1092852917000840 crossref_primary_10_1021_mp500070m |
| Cites_doi | 10.1016/S0025-6196(11)61533-4 10.1097/JCP.0b013e3181a289cb 10.1016/j.jconrel.2008.04.004 10.1097/00007435-197801000-00002 10.1186/1471-244X-10-43 10.7748/ns1999.06.13.39.47.c2623 10.1016/0378-4347(95)00061-M 10.1021/ja02086a003 10.1097/00004714-200102000-00004 10.1176/appi.ajp.2009.07081221 10.1002/jps.2600541119 10.7326/0003-4819-147-4-200708210-00021 10.2190/KNQT-UEU4-GAQ2-57L6 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 BioMed Central Ltd. Copyright ©2010 McDonnell et al; licensee BioMed Central Ltd. 2010 McDonnell et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: Copyright ©2010 McDonnell et al; licensee BioMed Central Ltd. 2010 McDonnell et al; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK 5PM DOA |
| DOI | 10.1186/1471-244X-10-45 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-244X |
| EndPage | 45 |
| ExternalDocumentID | oai_doaj_org_article_3f14849ffab440f0b51603cd909a8df5 PMC2895590 oai_biomedcentral_com_1471_244X_10_45 A230287006 20537130 10_1186_1471_244X_10_45 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C6C CCPQU CITATION CS3 DIK DWQXO E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GNUQQ GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ IPY ITC KQ8 M1P M2M M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 7TK -A0 3V. ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM PUEGO |
| ID | FETCH-LOGICAL-b616t-f83aed232ad6a7a44cefda2b21af0cd9729a17b1f37634fffd629336b7e573333 |
| IEDL.DBID | RBZ |
| ISSN | 1471-244X |
| IngestDate | Wed Aug 27 01:32:04 EDT 2025 Thu Aug 21 18:32:54 EDT 2025 Wed May 22 07:10:35 EDT 2024 Tue Aug 05 11:18:18 EDT 2025 Fri Jul 11 08:10:29 EDT 2025 Tue Jun 17 21:15:03 EDT 2025 Tue Jun 10 20:43:45 EDT 2025 Mon Jul 21 06:04:18 EDT 2025 Thu Apr 24 22:54:04 EDT 2025 Tue Jul 01 01:46:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b616t-f83aed232ad6a7a44cefda2b21af0cd9729a17b1f37634fffd629336b7e573333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://dx.doi.org/10.1186/1471-244X-10-45 |
| PMID | 20537130 |
| PQID | 733627390 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3f14849ffab440f0b51603cd909a8df5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2895590 biomedcentral_primary_oai_biomedcentral_com_1471_244X_10_45 proquest_miscellaneous_744698082 proquest_miscellaneous_733627390 gale_infotracmisc_A230287006 gale_infotracacademiconefile_A230287006 pubmed_primary_20537130 crossref_citationtrail_10_1186_1471_244X_10_45 crossref_primary_10_1186_1471_244X_10_45 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-06-10 |
| PublicationDateYYYYMMDD | 2010-06-10 |
| PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | BMC psychiatry |
| PublicationTitleAlternate | BMC Psychiatry |
| PublicationYear | 2010 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | S Sen (675_CR20) 2005; 80 HC Detke (675_CR2) 2010; 10 Eli Lilly and Company (675_CR9) 2009 R Bergstrom (675_CR7) 2000 JL Cummings (675_CR22) 1986; 16 L Citrome (675_CR8) 2009; 29 D Kurtz (675_CR11) 2008; 63 R Shrewsbury (675_CR4) 2008 PJ Perry (675_CR14) 2001; 21 TF Downham (675_CR16) 1978; 5 JM Kane (675_CR5) 2010; 167 B Workman (675_CR15) 1999; 13 JT Catlow (675_CR10) 1995; 668 Institute for Safe Medication Practices (675_CR19) 2006 Institute for Safe Medication Practices (675_CR18) 2004 WE Hamlin (675_CR13) 1965; 54 M Martinez (675_CR6) 2008; 129 European Medicines Agency (675_CR1) 2008 AA Noyes (675_CR12) 1987; 19 J Tang (675_CR21) 2007; 147 Novocol Pharmaceuticals of Canada, Inc (675_CR17) 2005 Electronic Medicines Compendium (675_CR3) 2009 3744684 - Int J Psychiatry Med. 1986-1987;16(2):163-8 17709768 - Ann Intern Med. 2007 Aug 21;147(4):283-4 7550985 - J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):85-90 15945530 - Mayo Clin Proc. 2005 Jun;80(6):783-95 11199942 - J Clin Psychopharmacol. 2001 Feb;21(1):14-20 417409 - Sex Transm Dis. 1978 Jan-Mar;5(1):4-9 20008947 - Am J Psychiatry. 2010 Feb;167(2):181-9 18514351 - J Control Release. 2008 Jul 14;129(2):79-87 20537128 - BMC Psychiatry. 2010;10:43 10497490 - Nurs Stand. 1999 Jun 16-22;13(39):47-53; quiz 54 19440083 - J Clin Psychopharmacol. 2009 Jun;29(3):278-83 |
| References_xml | – volume: 80 start-page: 783 year: 2005 ident: 675_CR20 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)61533-4 – volume: 29 start-page: 278 year: 2009 ident: 675_CR8 publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e3181a289cb – volume-title: Assessment report for Zypadhera year: 2008 ident: 675_CR1 – volume: 129 start-page: 79 year: 2008 ident: 675_CR6 publication-title: J Control Release doi: 10.1016/j.jconrel.2008.04.004 – volume: 5 start-page: 4 year: 1978 ident: 675_CR16 publication-title: Sex Transm Dis doi: 10.1097/00007435-197801000-00002 – volume-title: Applied pharmaceutics in contemporary compounding year: 2008 ident: 675_CR4 – volume: 10 start-page: 43 year: 2010 ident: 675_CR2 publication-title: BMC Psychiatry doi: 10.1186/1471-244X-10-43 – volume-title: ISMP medication safety alert: Bicillin products: syringe enhancements may help to prevent IV administration year: 2004 ident: 675_CR18 – volume: 13 start-page: 47 year: 1999 ident: 675_CR15 publication-title: Nurs Stand doi: 10.7748/ns1999.06.13.39.47.c2623 – volume-title: ISMP medication safety alert: Action needed to prevent serious tissue injury with IV promethazine year: 2006 ident: 675_CR19 – volume-title: Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection year: 2009 ident: 675_CR3 – volume-title: Zyprexa [package insert] year: 2009 ident: 675_CR9 – volume: 63 start-page: 288S issue: suppl 1 year: 2008 ident: 675_CR11 publication-title: Biol Psychiatry – volume: 668 start-page: 85 year: 1995 ident: 675_CR10 publication-title: J Chromatogr B Biomed Appl doi: 10.1016/0378-4347(95)00061-M – volume: 19 start-page: 930 year: 1987 ident: 675_CR12 publication-title: J Am Chem Soc doi: 10.1021/ja02086a003 – volume: 21 start-page: 14 year: 2001 ident: 675_CR14 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200102000-00004 – volume: 167 start-page: 181 year: 2010 ident: 675_CR5 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2009.07081221 – start-page: 232 volume-title: Olanzapine (Zyprexa): A novel antipsychotic year: 2000 ident: 675_CR7 – volume: 54 start-page: 1651 year: 1965 ident: 675_CR13 publication-title: J Pharm Sci doi: 10.1002/jps.2600541119 – volume: 147 start-page: 283 year: 2007 ident: 675_CR21 publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-4-200708210-00021 – volume-title: Septocaine with epinephrine [package insert] year: 2005 ident: 675_CR17 – volume: 16 start-page: 163 year: 1986 ident: 675_CR22 publication-title: Int J Psychiatry Med doi: 10.2190/KNQT-UEU4-GAQ2-57L6 – reference: 417409 - Sex Transm Dis. 1978 Jan-Mar;5(1):4-9 – reference: 11199942 - J Clin Psychopharmacol. 2001 Feb;21(1):14-20 – reference: 17709768 - Ann Intern Med. 2007 Aug 21;147(4):283-4 – reference: 15945530 - Mayo Clin Proc. 2005 Jun;80(6):783-95 – reference: 18514351 - J Control Release. 2008 Jul 14;129(2):79-87 – reference: 19440083 - J Clin Psychopharmacol. 2009 Jun;29(3):278-83 – reference: 7550985 - J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):85-90 – reference: 20537128 - BMC Psychiatry. 2010;10:43 – reference: 20008947 - Am J Psychiatry. 2010 Feb;167(2):181-9 – reference: 10497490 - Nurs Stand. 1999 Jun 16-22;13(39):47-53; quiz 54 – reference: 3744684 - Int J Psychiatry Med. 1986-1987;16(2):163-8 |
| SSID | ssj0017851 |
| Score | 2.221037 |
| Snippet | Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this... Background Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution... BACKGROUND: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution... Abstract Background Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 45 |
| SubjectTerms | Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacokinetics Benzodiazepines - administration & dosage Benzodiazepines - adverse effects Benzodiazepines - pharmacokinetics Care and treatment Clinical Trials as Topic - statistics & numerical data Complications and side effects Delayed-Action Preparations Dosage and administration Drug Overdose - etiology Drug Overdose - metabolism Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - metabolism Drugs Humans Injections, Intramuscular Olanzapine Overdose Research article Schizophrenia Schizophrenia - drug therapy Syndrome Treatment Outcome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gIB-Q4IDZZON1EjgVRNUilROV9mb5WYJ2vVWze-kf6d9lxnlorQq4cExsy7FnPI945htC3lQmL62tDONca4aQ5kxXc8-cLa1YKKWKiKV39l2cnPNvy8Vyr9QXxoT18MD9xs1KDwY7b7xXmvPc53qBhZGNbfJG1dZH9FLQeaMzNdwfYMn5mFdUFQwU2HIA9SlqMZveoQTCLKYk0X2V6KcI439bWO9pqzSSck81HT8g9webkh71a3lI7rjwiNw9G27NH5MbrMjL2vArhl0Fat2qvWp361nn-opKdMQtoG2gA9JqR_EXLe32g_JoDEt3tm8Cpzhcq0uYgq424YJhikS4oNM87-np6Ud4nIA8gMHpxtO1w2zjtls_IefHX398OWFDQQamRSG2zNelchZsMGWFqhTnxnmr5npeKJ8DScBQV0WlC49Si3vvrQBrohS6cgi7WJZPyUHYBPecUN2YShTG6cZq7p0BP9kZ4WoNQgd_dGXkU0IWedmDb0iEw05b4GRKJKpEokpwajiM_jASUZoB6xxLbqxk9HlqcXvAu2nAONMfu35Grkg-KL4ArpUD18p_cW1G3iJPSZQi8GFGDckQsDmIxyWPwDPEK-hcZOQw6Qmn3yTNdORKiU0YMhfcZtdJxLkE27TJ_9KFY_1QMAIz8qzn42lVc8T5AfsmI1XC4cmy05bQ_ozw5ODCg5uav_gf-_SS3OvDNQSc1kNysL3auVdgBW7163jgfwMqdl3W priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJvCgnxAggPZTRrXSUAILYjVLlI5Uak3y89uUOosTSsBf4S_y0we3Vq7cOCYjCdO7JnxTDz-hpAXmY5TYzIdMaZUhJDmkcrGLrImNXwipUxaLL3pF34yY5_nk_lFOaB-AJsrQzusJzVbVQc_vv98Dwr_rlX4nB8mYGAjWKbmaFPY5Dq5ActShlo6ZRdbCliFvsf2uYIJQYER2iTBdOjg6HsVrFgtsP9l872zfoW5lTuL1fEdcrv3MulRJxZ3yTXr75Gb034f_T75jTV6o9J_axOxPDW2KlflZnnY2K7GEh2QDGjpaY-92lD8aUub3TQ92iaqW9ORYCz9L3kOXdCq9osID034Bd3285qenr6Byy20B4g8rR1dWjx_XDbLB2R2_Onrx5OoL9EQKZ7wdeTyVFoDXpk0XGaSMW2dkWM1TqSLtSnAdZdJphKHdow55wwH_yLlKrMIxJimD8mer719TKgqdMYTbVVhFHNWQ-RsNbe5AjOEv75G5G0wLeK8g-MQCJAdUkBXBc6vwPkVEOYw4D4YJlHoHv0ci3BUoo2Ccn6Z4dWWYejpr00_oFQEL9TeqFcL0RsAkToIPFnhnFSMxS5WEyzwDUMUFzI3Dh7yEmVKoKTDi2nZH4-AwUGELnEEsSJuSsd8RPaDlmAPdECmg1QKJGESnbf1phGIfAneahH_ownDiqLgFo7Io06Ot181qMeIZIGEB58dUnx51gKWQ1APgWv85L85n5JbXdYGB23dJ3vr1cY-A2dwrZ63Sv4HueRjAA priority: 102 providerName: Scholars Portal |
| Title | Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20537130 https://www.proquest.com/docview/733627390 https://www.proquest.com/docview/744698082 http://dx.doi.org/10.1186/1471-244X-10-45 https://pubmed.ncbi.nlm.nih.gov/PMC2895590 https://doaj.org/article/3f14849ffab440f0b51603cd909a8df5 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELZoKyEuiDeBEvmABAeW7sOxd-HUoFYtUiqEqBRxsfwsixKnapILf4S_y8zuZolb4MIl0sb2endnPA975htCXgqTFtYKkzCmdYKQ5okWuU-cLSwfKaWyBktvcsZPztnH6Wj6Gyz62gl-VvKDDMRnAkpoihKDjXbIXs5ADaJjPv7aHxhgjfkmkajr3KH4_OEG1zLbZ5FCanD7b0rnLfUUh05u6aLje-RuZ0TSw5bq98ktFx6Q25PumPwh-YkleJM6fG_irAK1blZf1ev5wdK1JZToBqiA1oF20KpLinuydLkdhUebOHRn2ybwgsMPdQlT0NkiXCSYExEuaD_PG3p6-g4ue-QO4Gi68HTuML24Xs4fkfPjoy8fTpKuAkOiecZXiS8L5SwYXcpyJRRjxnmrcp1nyqfGVmCZq0zozKOYYt57y8F8KLgWDnEWi-Ix2Q2L4J4SqisjeGacrqxm3hlwjJ3hrtQgZXBna0DeR2SRly3ahkT867gFlqJEokokqgQvhsHotxsiStOBm2ONjZlsnJyS3xzwuh-wmemvXcfIFdEDNX8Al8pufcvCg1_JKu-VZiz1qR5h_W74RGmlSuvhJq-QpySKDXgwo7rsB_g4CMAlD8EVxDPnlA_IftQTlruJmumGKyU2YYxccIv1UiKwJRijVfqPLgwLhoLVNyBPWj7u3ypHYB8waAZERBwevXbcEupvDR45-Ozgl6bP_ouCz8mdNjCDwzLdJ7urq7V7AfbeSg_JjpiKIdkbH519-jxsdk3gd8LKYSMDfgESJlqG |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKkYAL4s2WAj4gwYG0ycZxNnBqEdUudHtArbTiYvm5pMp6q83uhT_C32UmLzYUuHBMxo7jzHg8E898Q8irVIexMakOGFMqQEjzQKVDF1gTG55IKaMKS296xscX7NMsme2QcZsLoxb6V5jvwXYKelHp7TZcrF7tI34YgXYNYI-aoUJhyQ1yM02SFGsZfDn-2p0nYAn6Ks-oadyA_PzhAb8lvhe9_aqC9b-uvLd2r35k5dZWdXKP3G1sTHpUT-I-2bH-Abk1bU7RH5IfWKE3yP1lFYblqbFFvso3i8PS1hWWaItjQHNPG-TVkuIvW1puB-nRKkzdmpoETrL_Lq9gCFos_TzAlAk_p904b-lk8g4uO2APEHi6dHRhMfs4LxePyMXJx_MP46Ap0BAoHvF14EaxtAZsMmm4TCVj2jojh2oYSRdqk4HhLqNURQ61GHPOGQ7WRcxVahGGMY4fk12_9PYpoSrTKY-0VZlRzFkNfrPV3I4UKCH88TUg73tsEVc1GIdAeOw-BcREIFMFMlWAk8Og90HLRKEb7HMswVGIygca8esd3nQd2pH-2vQYpaL3QtWN5WouGnEVsQO3k2XOScVY6EKVYHlv-ERhJkfGwUNeo0wJ1CrwYlo2yRHwcRCfSxyBp4hH0iEfkP1eS9AGukemrVQKJGEInbfLTSkQ9xJs1Sz8RxOG9UTBKByQJ7Ucd7MaIu4P2DsDkvYkvDftPsXn3yq4cnDpwW0N9_6Lgy_J7fH59FScTs4-PyN36hgODkt2n-yuVxv7HEzDtXpRrfqfQgNl-g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgkVZcEG8KC_iABAeyTRrHSeC0C1RbYFcIsVLFxfKzBFK3atoLf4S_y0yShoYFLtzajh03mYdn4plvCHmS6jA2JtUBY0oFCGkeqHTkAmtiwxMpZVRj6Z2e8ZNz9naaTFtIIayFUXP9K833cLcEvaztNnzQ34ZL4xp1z_gwAvMawCY1RYvCksvkSpokKerox-PP3YEC9qCvC43awS3Kzx8u8Fvle9nbsGpc_4vWe2f76qdW7uxV4-vkWutk0qNGKm6QS9bfJPun7TH6LfIDW_QGhf9a52F5amxZrIrNfFjZpsUS3QIZ0MLTFnq1ovjOlla7WXq0zlO3piFBlOy_yyUsQcuFnwVYM-FntFvnOZ1MXsDXDtkDJJ4uHJ1bLD8uqvltcj5-8-nVSdB2aAgUj_g6cFksrQGnTBouU8mYts7IkRpF0oXa5OC5yyhVkUMzxpxzhoN7EXOVWsRhjOM7ZM8vvL1HqMp1yiNtVW4Uc1ZD4Gw1t5kCK4RvvgbkZY8tYtmgcQjEx-5TQE4EMlUgUwVEOQxmH26ZKHQLfo49OEpRB0EZvzjhWTdhu9Jfhx6jVPT-UP3DYjUTrf6L2EHcyXLnpGIsdKFKsL83PKIwl5lxcJGnKFMCzQrKuGyrI-DhIECXOIJQEc-kQz4gB72RYA50j0y3UimQhDl03i42lUDgS3BW8_AfQxg2FAWvcEDuNnLc3dUIgX_A4RmQtCfhvdvuU3zxpcYrh5ge4tbw_n9x8DHZ__B6LN5Pzt49IFebHA4OGntA9tarjX0IruFaPaqV_ieWhGXF |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Post-injection+delirium%2Fsedation+syndrome+in+patients+with+schizophrenia+treated+with+olanzapine+long-acting+injection%2C+II%3A+investigations+of+mechanism&rft.jtitle=BMC+psychiatry&rft.au=McDonnell%2C+David+P&rft.au=Detke%2C+Holland+C&rft.au=Bergstrom%2C+Richard+F&rft.au=Kothare%2C+Prajakti&rft.date=2010-06-10&rft.pub=BioMed+Central&rft.eissn=1471-244X&rft.volume=10&rft.spage=45&rft.epage=45&rft_id=info:doi/10.1186%2F1471-244X-10-45&rft_id=info%3Apmid%2F20537130&rft.externalDocID=PMC2895590 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-244X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-244X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-244X&client=summon |